Venöse Thrombembolien bei Tumorpatienten

Summary

Venous thrombembolism (VTE) is one of the most frequent complication in cancer patients. The current options in prophylaxis and therapy have to be balanced against the risks of major bleeding and the burden for the patients. The Gesellschaft für Thrombose- und Hämostaseforschung, the Deutsche Gesellschaft für Palliativmedizin and the German speaking Societies of Hematology and Oncology have recently published guidelines on VTE in cancer patients. Recommendations include diagnostics, individual prophylaxis and treatment.

Zusammenfassung

Venöse Thrombembolien (VTE) gehören zu den häufigen Komplikationen bei Tumorpatienten und sind ein prognostisch ungünstiges Zeichen. Die aktuellen und effizienten Möglichkeiten der medikamentösen Prophylaxe und Therapie sind abzuwägen gegen das Blutungsrisiko und die Belastungen für den Patienten. Gemeinsam mit der Gesellschaft für Thrombose- und Hämostaseforschung und der Deutschen Gesellschaft für Palliativmedizin haben die deutschsprachigen Fachgesellschaften der Hämatologie und Onkologie kurzgefasste Leitlinien erarbeitet. Schwerpunkte sind die rationelle Diagnostik, Indikationen zur Prophylaxe in Abhängigkeit von den individuellen Risikofaktoren und die Differenzialtherapie.

Keywords

Cancer - tumour - venous thrombosis - pulmonary embolism - venous thromboembolism

Schlüsselwörter

Krebserkrankung - Tumor - Venenthrombose - Pulmonalembolie - Venöse Thromboembolie

• References

• 1 Ay C., Pabinger I.. Test predictive of thrombosis in cancer. Thromb Res 2010; 125 (Suppl. 02) S12-S15.
• 2 Ay C., Dunkler D., Marosi C. et al. Prediction of venous thrombembolism in cancer patients. Blood 2010; 116: 5377-5372.
• 3 Carrier M., Le Gal G., Wells PS. et al. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism. Ann Int Med 2008; 140: 323-333.
• 4 Carrier M., Le Gal G., Tay J. et al. Thromboprophylaxis in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide and lenalidomide: a systematic review and meta-analysis. Meeting of the American Society of Hematology, Abstract 1090, 2010.
• 5 Connolly GC, Khorana AK.. Emerging risk stratification approaches to cancer-associated thrombosis: risk factors, biomarkers and a risk score. Thromb Res 2010; 125 (Suppl. 02) S1-S7.
• 6 Falanga A., Marchetti M.. Venous thromboembolism in the hematologic malignancies. J Clin Oncol 2009; 27: 4848-4857.
• 7 Hylek EM.. Therapeutic potential of oral factor Xa inhibitors. N Engl J Med 2 2010; 363: 2559-2561.
• 8 Kakkar AK.. Prevention of venous thromboembolism in the cancer surgical patient. J Clin Oncol 2009; 29: 2881-4884.
• 9 Kearon C., Kahn SR, Agnelli G. et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8^th . Chest 2008; 133: 454S-545S.
• 10 Khorana AA, Connolly GC.. Assessing risk for venous thromboembolism in the patients with cancer. J Clin Oncol 2009; 27: 4839-4847.
• 11 Lee AY.. Anticoagulation in the treatment of established venous thromboembolism in patients with cancer. J Clin Oncol 2009; 27: 4895-4901.
• 12 Le Gal G., Righini M., Roy PM. et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 2006; 144: 165-171.
• 13 Lewandowski B., Kovacs MJ.. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003; 349: 1227-1235.
• 14 Lyman GH, Khorana AA, Falanga A. et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-5505.
• 15 Mandala M., Labianca R.. Venous thromboembolism (VTE) in cancer patients. ESMO clinical recommendations for prevention and management. Thromb Res 2010; 125 (Suppl. 02) S117-S119.
• 16 Palumbo A., Rajkumar SV, Dimopoulos MA. et al. Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414-423.
• 17 Perry JR, Julian JA, Laperriere NJ. et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 8: 1959-1965.
• 18 Piccioli A., Lensing AW, Prins MH. et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost 2004; 2: 884-889.
• 19 Rana P., Levine MN.. Prevention of thrombosis in ambulatory patients with cancer. J Clin Oncol 2009; 29: 4885-4888.
• 20 Riess H., Pelzer U., Opitz M. et al. A prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the CONKO-004 trial. J Clin Oncol 2010; 28 (Suppl): Abstract 4033.
• 21 S2-Leitlinie zur Diagnostik und Therapie der Venenthrombose und der Lungenembolie in Deutschland 2010. http://www.awmf.org/leitlinien/detail/ll/065-002.html.
• 22 Shivakumar SP, Anderson DR, Couban S.. Catheter-associated thrombosis in patients with malignancy. J Clin Oncol 2009; 27: 4858-4864.
• 23 Streiff MB.. The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. Thromb Res 2010; 125 (Suppl. 02) S128-S133.
• 24 Tran QNH.. Role of palliative low-molecular-weight heparin for treating venous thromboembolism in patients with advanced cancer. Am J Hosp Palli Med 2010; 27: 416-419.
• 25 Wells PS, Hirsh J., Anderson DR. et al. Accuracy of clinical assessment of deep vein thrombosis. Lancet 1995; 345: 1326-1330.
• 26 Wells PS, Ginsberg JS, Anderson DR. et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med 1998; 129: 997-1005.